
Opinion|Videos|April 18, 2025
Closing Insights: The Future of Cemiplimab in NSCLC and Beyond
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more personalized, targeted approaches. This will enhance survival outcomes, refine patient selection and optimize therapy regimens.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- As new data on cemiplimab and other checkpoint inhibitors continue to emerge, how do you anticipate the overall treatment pathway for cancers like NSCLC will change?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
PBM reform. It has finally happened
3
Cancer survival fell and deaths rose during first two years of COVID-19
4
TrumpRx launches; some experts question its long-term value
5



























